Analysed LEXEO THERAPEUTICS INC (LXEO:NASDAQ) News Sources
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
05-08-2026
yahoo.com
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
30-03-2026
yahoo.com
Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
27-04-2026
yahoo.com
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19-05-2026
yahoo.com
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
15-06-2026
yahoo.com
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
17-06-2026
yahoo.com
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?
02-07-2026
yahoo.com
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple
15-07-2026
yahoo.com
What is the current price of LEXEO THERAPEUTICS INC (LXEO:NASDAQ)?
The current price of LEXEO THERAPEUTICS INC (LXEO:NASDAQ) is $4.92.
LEXEO THERAPEUTICS INC (LXEO:NASDAQ) absolute price change since previous trading day?
The absolute price change of LEXEO THERAPEUTICS INC (LXEO:NASDAQ) since the previous trading day is $0.04.
LEXEO THERAPEUTICS INC (LXEO:NASDAQ) percentage price change since previous trading day?
The percentage price change of LEXEO THERAPEUTICS INC (LXEO:NASDAQ) since the previous trading day is 0.8197%.
What is the most recent average sentiment score for LEXEO THERAPEUTICS INC (LXEO:NASDAQ)?
The most recent average sentiment score for LEXEO THERAPEUTICS INC (LXEO:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for LEXEO THERAPEUTICS INC (LXEO:NASDAQ)?
The most recent sentiment for LEXEO THERAPEUTICS INC (LXEO:NASDAQ) is .
SEC-8K** Filing Available For LEXEO THERAPEUTICS INC (LXEO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.